Summary On May 28th, 2015, Fairway is scheduled to report its earnings from its last quarter. During the last quarter, the EURO dollar weakened substantially while the dollar gained. This factor has likely been over looked by the analysts covering…
Tag: Acquisition
The Biotech Merger And Acquisition Buzz List
Merger and acquisition rumors are heard on a daily basis throughout the market. Some have merit and turn out to be true, while others turn out to be false and without merit. Today, I will cover some companies that I…
Important Upcoming Catalyst For Antares – FDA Decision Expected October 14
n a bit more deliberate than Jazz, but is coming along nicely. Antares started its royalty deals with a gel based platform, one being a royalty deal with Actavis, Inc. (NYSE: ACT) (formely Watson Pharma) for topical oxybutynin gel. Oxybutynin…
Bullish Free Articles Bullish Premium Articles Commentary Free Articles Commentary Premium Articles Free Articles Premium Articles
Edited: Is An Acquisition Of Solta Medical Imminent?
In my last article concerning Solta Medical Devices (SLTM), I remarked several times how I feel the company has good assets and the potential to grab significant market share in various segments. However, I do feel the company and its…
Voce Capital Pushes For Acquisition Of Solta Medical, Activist Investor David Callan Joins In
Merger and acquisition speculation is one of the most interesting and exciting elements of the stock market. Sometimes both activist institutions and private investors can leverage deals or stop deals from happening depending on how many shares they control in…
Trius Acquired Last Week, Tetraphase Could Be Next
Written by Scott Matusow, Mr.Matusow holds a position in the company featured in this article. Last week, Cubist Pharmaceuticals Inc. (CBST) agreed to buy Trius Therapeutics Inc. (TSRX) and Optimer Pharmaceuticals Inc. (OPTR) for as much as $1.62 billion. Cubist…
4 Top Small Cap Biotech Acquisition Targets
Today, I list small cap companies I believe are top acquisition targets for large pharma. I combine speculation, rumors and buzz I am hearing, and company financial position as a few factors for consideration. Buy-outs are hard to predict in…
Voce Capital Management Goes Hardball With Proxy Fight Against Obagi Board
Another chapter has been written on the nearly year long effort by Voce Capital management to get Obagi Medical Products (OMPI) sold, when on Monday, 12/3/12, Voce made public another letter sent to the Obagi Board of Directors (BOD) In…
